Publications

Healthcare Provider Awareness and Integration of Immunotherapy for Stage III NSCLC

This poster, presented at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium, reports an analysis of healthcare provider uptake of immune checkpoint inhibitor therapy for the treatment of unresectable stage III NSCLC in the 9 months following its approval. Self-reported practice trends at baseline showed that most HCPs were not optimally treating unresectable stage III NSCLC prior to attending the symposia. However, post-education data suggest that HCPs are willing to modify their practice in this setting after receiving expert led education and guidance.